William Blair

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) on Monday announced plans to separate its Minimal Residual Disease (MRD) and Immune Medicine businesses. • Adaptive Biotechnologies stock is trending lower. Why are ADPT shares declining? Adaptive Separation Plan Could Sharpen Focus On MRD...

Incyte Corporation (NASDAQ:INCY) said Monday it has agreed to acquire Vega Therapeutics, a wholly owned subsidiary of Star Therapeutics, in a deal valued at $1.25 billion upfront. The transaction will add late-stage candidate VGA039 to Incyte's hematology portfolio and could reach a total value of...

Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP) shares are down on Tuesday as the company announced broad alignment with the FDA regarding the registration path for its CRB-701 treatment. • Corbus Pharmaceuticals stock is showing weakness. What’s driving CRBP stock lower? FDA...

William Blair upgraded 10x Genomics Inc. (NASDAQ:TXG) stock, citing it as the best-in-class technology and is well-positioned to benefit from recovering end-markets and emerging demand for large-scale biological datasets to train AI models. • 10x Genomics shares are powering higher. What...

The U.S. Food and Drug Administration Commissioner Marty Makary confirmed on Friday that Dr. Vinay Prasad, head of its Center for Biologics Evaluation and Research (CBER), is set to leave his position in April. • Moderna shares are trending higher. Why is MRNA stock advancing? CBER is...

Avantor Inc. (NYSE:AVTR) stock is trading lower on Wednesday after the company reported fourth-quarter adjusted earnings of 22 cents, in line with the consensus. • Avantor shares are approaching critical lows. Why is AVTR stock at lows? The life science tools company reported sales of $1.66...

Kyowa Kirin Co., Ltd. and Amgen Inc. (NASDAQ:AMGN) terminated on Friday the current rocatinlimab development and commercialization collaboration. • Amgen stock is trading at elevated levels. Where are AMGN shares going? Kyowa Kirin will regain control of the global rocatinlimab program,...

At a J.P. Morgan Healthcare Conference on Monday, Amgen Inc.(NASDAQ:AMGN) CEO Robert Bradway shared findings from part 2 of the Phase 2 Study of MariTide, its investigational obesity treatment. • Amgen stock is showing positive momentum. What’s the outlook for AMGN shares? Key Findings...

uniQure N.V. (NASDAQ:QURE) stock is trading lower on Thursday. • QURE shares are retreating from recent levels. Check the market position here. The gene therapy company received final meeting minutes from the U.S. Food and Drug Administration regarding a pre-Biologics License Application (BLA)...

Bayer AG (OTC:BAYRY) released topline results from the Phase 3 OCEANIC-STROKE study, with its investigational, once daily, oral FXIa inhibitor asundexian. • BMY shares are climbing. Find out why here. The study met its primary efficacy and safety endpoints. Asundexian 50 mg once daily...

Intuitive Surgical (NASDAQ:ISRG) reported revenue of $2.51 billion for the third quarter, up 23% year-over-year, beating analyst estimates of $2.40 billion. • ISRG shares are powering higher on strong volume. Review the technical setup here. The company reported third-quarter adjusted...

Thermo Fisher Scientific Inc. (NYSE:TMO) on Wednesday reported third-quarter 2025 adjusted earnings of $5.79 per share, beating the street view of $5.49. • TMO stock is showing upward bias. Get the inside scoop here. Quarterly sales of $11.12 billion increased 5% year-over-year,...

The U.S. Food and Drug Administration extended on Monday Denali Therapeutics Inc.’s (NASDAQ:DNLI) review timeline of the Biologics License Application (BLA), seeking accelerated approval of tividenofusp alfa for the treatment of mucopolysaccharidosis type II (MPS II), also known as Hunter...

Tesla Inc. (NASDAQ:TSLA) CEO Elon Musk has spoken out about the “Big Beautiful Bill” backed by President Donald Trump and Congress on several occasions. The bill will make it more expensive for consumers to buy electric vehicles and provide less credits for EV companies. One analyst...

Nektar Therapeutics (NASDAQ:NKTR) released on Tuesday statistically significant data from the 16-week induction period of the ongoing Phase 2b REZOLVE-AD study of investigational rezpegaldesleukin. The trial met its primary endpoint of the mean improvement in Eczema Area and Severity Score (EASI)...